Basic Study
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Cardiol. Jun 26, 2023; 15(6): 293-308
Published online Jun 26, 2023. doi: 10.4330/wjc.v15.i6.293
Identification of potential biomarkers for idiopathic pulmonary fibrosis and validation of TDO2 as a potential therapeutic target
Ru Wang, Yan-Mei Yang
Ru Wang, Henan University of Chinese Medicine, Collaborative Innovation Centre for Chinese Medicine and Respiratory Diseases, Zhengzhou 450046, Henan Province, China
Yan-Mei Yang, Zhengzhou University, Research Centre of Basic Medicine, Academy of Medical Sciences, Zhengzhou 450000, Henan Province, China
Author contributions: Yang YM designed the research study; Wang R and Yang YM performed the research; Yang YM analysed the data and wrote the manuscript; Wang R performed the experiment research; all authors have read and approved the final manuscript.
Institutional review board statement: Our manuscript involves experiments on mice, as well as the A549 and IMR-90 cell lines, but does not involve any human experimentation.
Institutional animal care and use committee statement: The study was reviewed and approved by the Experimental Animal Ethics Committee of Henan University of Chinese Medicine, No. DWLLGZR202202036.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: The authors confirm that the data supporting the findings of this study are available.
ARRIVE guidelines statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yan-Mei Yang, PhD, Doctor, Zhengzhou University, Research Centre of Basic Medicine, Academy of Medical Sciences, No. 40 North University Road, Erqi District, Zhengzhou 450000, Henan Province, China. yang_yanmei@gs.zzu.edu.cn
Received: April 14, 2023
Peer-review started: April 14, 2023
First decision: May 17, 2023
Revised: June 1, 2023
Accepted: June 13, 2023
Article in press: June 13, 2023
Published online: June 26, 2023
Processing time: 73 Days and 6 Hours
Core Tip

Core Tip: This study is unique in several aspects: (1) We identified six hub genes for idiopathic pulmonary fibrosis (IPF) and determined through quantitative real-time polymerase chain reaction; (2) Multi-omics analysis proved that TDO2 was upregulated in IPF patients and promoted the IPF proliferation of fibroblasts; (3) TDO2 may be involved in P53 pathway and aggravate aging and persistent pulmonary fibrosis; and (4) TDO2 inhibitor effectively suppressed transforming growth factor-β-induced fibroblast activation.